Methodological commentary demonstrates limitations of patient-level adverse event tracking during intravenous immunoglobulin therapy, highlighting the need for exposure-adjusted safety analyses.
Adverse events during intravenous immunoglobulin treatment were analyzed at the patient level, although cumulative treatment exposure varied across dermatologic indications. I highlight that patient-level adverse-event frequencies may therefore not reflect exposure-adjusted IVIG risk and suggest that cycle-based or exposure-adjusted analyses could strengthen interpretation of the study’s safety findings.
No takes yet. Share an insight, caveat, or question.
Fatih Kaplan (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: